Terms: = Ovarian cancer AND FANCE, 2178, ENSG00000112039, FAE
11 results:
1. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan RD; Clamp AR; Barnes BM; Timms K; Schlecht H; Yarram-Smith L; Wallis Y; Valganon-Petrizan M; MacMahon S; White R; Morgan S; McKenna S; Hudson E; Tookman L; George A; Manchanda R; Sundar SS; Nicum S; Brenton JD; Kristeleit RS; Banerjee S; McNeish IA; Ledermann JA; Taylor SS; Evans DGR; Jayson GC
Int J Gynecol Cancer; 2023 Aug; 33(8):1253-1259. PubMed ID: 37072323
[TBL] [Abstract] [Full Text] [Related]
2.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
3. Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.
Ye S; Wu J; Yao L; He J
J Clin Pathol; 2022 Nov; 75(11):776-781. PubMed ID: 34348985
[TBL] [Abstract] [Full Text] [Related]
4. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
5. First clinical experiences with a high field 1.5 T MR linac.
Bertelsen AS; Schytte T; Møller PK; Mahmood F; Riis HL; Gottlieb KL; Agergaard SN; Dysager L; Hansen O; Gornitzka J; Veldhuizen E; ODwyer DB; Christiansen RL; Nielsen M; Jensen HR; Brink C; Bernchou U
Acta Oncol; 2019 Oct; 58(10):1352-1357. PubMed ID: 31241387
[No Abstract] [Full Text] [Related]
6. The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
Timmermans M; van der Hel O; Sonke GS; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Gynecol Oncol; 2019 May; 153(2):445-451. PubMed ID: 30826010
[TBL] [Abstract] [Full Text] [Related]
7. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract] [Full Text] [Related]
8. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer.
Esteban-Jurado C; Franch-Expósito S; Muñoz J; Ocaña T; Carballal S; López-Cerón M; Cuatrecasas M; Vila-Casadesús M; Lozano JJ; Serra E; Beltran S; Brea-Fernández A; Ruiz-Ponte C; Castells A; Bujanda L; Garre P; Caldés T; Cubiella J; Balaguer F; Castellví-Bel S
Eur J Hum Genet; 2016 Oct; 24(10):1501-5. PubMed ID: 27165003
[TBL] [Abstract] [Full Text] [Related]
9. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract] [Full Text] [Related]
10. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract] [Full Text] [Related]
11. A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer.
Worsham MJ; Nathanson SD; Pals G; Christopherson P; Strunk M; Wolman SR
Diagn Mol Pathol; 1998 Jun; 7(3):164-7. PubMed ID: 9836072
[TBL] [Abstract] [Full Text] [Related]
